biotech
Sichuan Kelun-Biotech Biopharmaceutical
Sichuan Kelun-Biotech Biopharmaceutical Co.,
NovaPharmaNews editorial coverage mentioning Sichuan Kelun-Biotech Biopharmaceutical — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- CN
- Programs
- 0
- Drugs
- 0
- Patents
- 0
News & analysis
NovaPharmaNews articles mentioning Sichuan Kelun-Biotech Biopharmaceutical — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Sichuan Kelun-Biotech Biopharmaceutical — regulatory, clinical, and market analysis.
Kelun-Biotech Secures New Drug Approval for SKB118: Investor and BD Guide
Kelun-Biotech has secured Investigational New Drug (IND) approval from China's CDE for its novel PD-1 x VEGF bispecific antibody, SKB118. This milestone opens the door for clinical development and presents significant opportunities and competitive considerations for the pharmaceutical industry.
Merck's TroFuse-005 Trial Results: Implications for Investors and Pharma Teams
Merck's TroFuse-005 trial evaluating Sacituzumab Tirumotecan has met primary endpoints of overall survival and progression-free survival in advanced endometrial cancer. This article explores the implications for investors and pharmaceutical teams.
Merck-Kelun ADC's Strategic Wins and Takeda's Antitrust Loss
This article delves into Merck-Kelun ADC's recent achievements in China and the implications of Takeda's significant antitrust loss, providing strategic insights for business development teams and investors.
Merck-Kelun Lung Cancer Drug Cuts Tumor Progression Risk by 65%
Merck-Kelun's recent trial results indicate a significant breakthrough in lung cancer treatment, with a 65% reduction in tumor progression risk. This article explores the implications for the pharmaceutical industry.
#ASCO26: Kelun's Phase 3 Lung Cancer Success with Merck
Kelun's Phase 3 study on lung cancer in partnership with Merck showcased significant success at ASCO26. This article explores the implications for the pharma industry.
Kelun and Merck's Lung Cancer Combo Shows Promise in China
Kelun and Merck's combination therapy for lung cancer has demonstrated improved survival rates in a late-stage trial in China, raising investment interest.
Merck’s Billion-Dollar Bet on TROP2: Regulatory Updates and Implications
Merck's strategic investment in Kelun-Biotech's TROP2 shows promising survival benefits in endometrial cancer. This analysis covers the regulatory updates and their implications for investors.